TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors
出版年份 2020 全文链接
标题
TP53 dysfunction in chronic lymphocytic leukemia: clinical relevance in the era of B-cell receptors and BCL-2 inhibitors
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume -, Issue -, Pages 1-12
出版商
Informa UK Limited
发表日期
2020-06-17
DOI
10.1080/13543784.2020.1783239
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Feasibility and efficacy of CD19-targeted CAR-T cells with concurrent ibrutinib for CLL after ibrutinib failure
- (2020) Jordan Gauthier et al. BLOOD
- International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia
- (2020) Adalgisa Condoluci et al. BLOOD
- A predictive tool for early-stage CLL
- (2020) Constantine S. Tam et al. BLOOD
- ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2020) Paolo Ghia et al. JOURNAL OF CLINICAL ONCOLOGY
- Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
- (2020) Jeff P Sharman et al. LANCET
- Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study
- (2020) Massimo Gentile et al. LEUKEMIA
- Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations and clinical impact
- (2019) Panagiotis Baliakas et al. BLOOD
- Minimal residual disease and survival outcomes in patients with chronic lymphocytic leukemia: A systematic review and meta-analysis.
- (2019) Stefano Molica et al. Clinical Lymphoma Myeloma & Leukemia
- Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations
- (2019) Jacob D Soumerai et al. Lancet Haematology
- Safety and efficacy analysis of long-term follow up real-world data with ibrutinib monotherapy in 58 patients with CLL treated in a single-center in Greece
- (2019) Maria Dimou et al. LEUKEMIA & LYMPHOMA
- Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
- (2019) Tait D. Shanafelt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
- (2019) Kirsten Fischer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Final analysis from RESONATE: up to 6 years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
- (2019) Talha Munir et al. AMERICAN JOURNAL OF HEMATOLOGY
- Undetectable MRD Using Next Generation Sequencing is Associated With Improved PFS After Treatment with FCR for CLL.
- (2019) Philip A Thompson et al. BLOOD
- Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study
- (2019) Carmen D Herling et al. LANCET ONCOLOGY
- Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia
- (2019) Gilles Salles et al. ANNALS OF HEMATOLOGY
- Prognostic Testing and Treatment Patterns in Chronic Lymphocytic Leukemia in the Era of Novel Targeted Therapies: Results from the informCLL™ Registry
- (2019) Anthony R. Mato et al. Clinical Lymphoma Myeloma & Leukemia
- Sequential and combination treatments with novel agents in chronic lymphocytic leukemia
- (2019) Moritz Fürstenau et al. HAEMATOLOGICA
- Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
- (2019) Jan A. Burger et al. LEUKEMIA
- The role of MYC in the transformation and aggressiveness of ‘indolent’ B-cell malignancies
- (2019) Daniel Filip et al. LEUKEMIA & LYMPHOMA
- Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia
- (2019) Yasir Khan et al. Expert Review of Hematology
- Chronic lymphocytic leukemia international prognostic index (CLL-IPI) in patients receiving chemoimmuno or targeted therapy: a systematic review and meta-analysis
- (2018) Stefano Molica et al. ANNALS OF HEMATOLOGY
- Biology and treatment of Richter syndrome
- (2018) Davide Rossi et al. BLOOD
- Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials
- (2018) Jeffrey Jones et al. BRITISH JOURNAL OF HAEMATOLOGY
- Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2
- (2018) Paul M. Barr et al. HAEMATOLOGICA
- Real world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study
- (2018) Antonio Cuneo et al. HAEMATOLOGICA
- Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial
- (2018) Stephan Stilgenbauer et al. JOURNAL OF CLINICAL ONCOLOGY
- BCL-2 as therapeutic target for hematological malignancies
- (2018) Guilherme Fleury Perini et al. Journal of Hematology & Oncology
- Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab
- (2018) Massimo Gentile et al. LEUKEMIA
- ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation
- (2018) J. Malcikova et al. LEUKEMIA
- Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
- (2018) John F. Seymour et al. NEW ENGLAND JOURNAL OF MEDICINE
- The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index
- (2018) Carolina Muñoz-Novas et al. Biomed Research International
- Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2
- (2018) Paul M. Barr et al. HAEMATOLOGICA
- Real world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States
- (2018) Anthony R. Mato et al. HAEMATOLOGICA
- Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study
- (2018) Antonio Cuneo et al. HAEMATOLOGICA
- Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment
- (2018) Massimo Gentile et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells
- (2018) Katerina Cerna et al. LEUKEMIA
- TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics
- (2018) Elias Campo et al. HAEMATOLOGICA
- Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow-up of the Swedish compassionate use cohort
- (2018) Maria Winqvist et al. HAEMATOLOGICA
- Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
- (2018) Carol Moreno et al. LANCET ONCOLOGY
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
- (2018) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
- (2017) Andrew D Zelenetz et al. LANCET ONCOLOGY
- Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL
- (2017) J R Brown et al. LEUKEMIA
- Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
- (2017) Kanaga Sabapathy et al. Nature Reviews Clinical Oncology
- Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation
- (2016) Mohamed A. Kharfan-Dabaja et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism
- (2016) M. A. Anderson et al. BLOOD
- Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
- (2016) M. Winqvist et al. HAEMATOLOGICA
- An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data
- (2016) LANCET ONCOLOGY
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
- (2016) Stephan Stilgenbauer et al. LANCET ONCOLOGY
- Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
- (2016) Asher Chanan-Khan et al. LANCET ONCOLOGY
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
- (2016) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-World Evidence — What Is It and What Can It Tell Us?
- (2016) Rachel E. Sherman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
- (2016) M. Winqvist et al. HAEMATOLOGICA
- Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: The French intergroup experience
- (2015) Luc-Matthieu Fornecker et al. AMERICAN JOURNAL OF HEMATOLOGY
- Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
- (2015) D. Rossi et al. BLOOD
- Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia
- (2015) P. A. Thompson et al. BLOOD
- Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial
- (2015) K. Fischer et al. BLOOD
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
- (2014) S. Stilgenbauer et al. BLOOD
- Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia
- (2014) D. Rossi et al. BLOOD
- Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach
- (2014) G. Doreen te Raa et al. BRITISH JOURNAL OF HAEMATOLOGY
- TP53 Mutants in the Tower of Babel of Cancer Progression
- (2014) Alessandra Bisio et al. HUMAN MUTATION
- Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia
- (2014) J Malcikova et al. LEUKEMIA
- Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
- (2014) John C. Byrd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice
- (2013) Francesco Zaja et al. AMERICAN JOURNAL OF HEMATOLOGY
- ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin
- (2013) V. Navrkalova et al. HAEMATOLOGICA
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
- (2012) Bernard Leroy et al. NUCLEIC ACIDS RESEARCH
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Missense Mutations Located in Structural p53 DNA-Binding Motifs Are Associated With Extremely Poor Survival in Chronic Lymphocytic Leukemia
- (2011) Martin Trbusek et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutant p53-induced Up-regulation of Mitogen-activated Protein Kinase Kinase 3 Contributes to Gain of Function
- (2010) Aymone Gurtner et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- TP53Mutation and Survival in Chronic Lymphocytic Leukemia
- (2010) Thorsten Zenz et al. JOURNAL OF CLINICAL ONCOLOGY
- TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations
- (2010) T Zenz et al. LEUKEMIA
- The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness
- (2009) D. Rossi et al. CLINICAL CANCER RESEARCH
- MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes
- (2009) Marek Mraz et al. LEUKEMIA & LYMPHOMA
- Mutant p53 Gain-of-Function in Cancer
- (2009) M. Oren et al. Cold Spring Harbor Perspectives in Biology
- Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up
- (2008) T. Zenz et al. BLOOD
- A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease
- (2008) O G Best et al. LEUKEMIA
- A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL
- (2008) O G Best et al. LEUKEMIA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started